Search

Your search keyword '"van Werkhoven E"' showing total 57 results
Start Over Author "van Werkhoven E" Publication Type Electronic Resources
57 results on '"van Werkhoven E"'

1. High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer:the randomized phase III NeoTN trial

Author

Vliek, S, Hilbers, FS, van Werkhoven, E, Mandjes, I, Kessels, R, Kleiterp, S, Lips, EH, Mulder, L, Kayembe, MT, Loo, CE, Russell, NS, Peeters, MJTFDV, Holtkamp, MJ, Schot, M, Baars, JW, Honkoop, AH, Vulink, AJE, Imholz, ALT, Vrijaldenhoven, S, van den Berkmortel, FWPJ, Terwogt, JMM, Schrama, JG, Kuijer, P, Kroep, JR, van der Padt-pruijsten, A, Wesseling, J, Sonke, GS, Gilhuijs, KGA, Jager, A, Nederlof, P, Linn, SC, Vliek, S, Hilbers, FS, van Werkhoven, E, Mandjes, I, Kessels, R, Kleiterp, S, Lips, EH, Mulder, L, Kayembe, MT, Loo, CE, Russell, NS, Peeters, MJTFDV, Holtkamp, MJ, Schot, M, Baars, JW, Honkoop, AH, Vulink, AJE, Imholz, ALT, Vrijaldenhoven, S, van den Berkmortel, FWPJ, Terwogt, JMM, Schrama, JG, Kuijer, P, Kroep, JR, van der Padt-pruijsten, A, Wesseling, J, Sonke, GS, Gilhuijs, KGA, Jager, A, Nederlof, P, and Linn, SC

Abstract

Exploratory analyses of high-dose alkylating chemotherapy trials have suggested that BRCA1 or BRCA2-pathway altered (BRCA-altered) breast cancer might be particularly sensitive to this type of treatment. In this study, patients with BRCA-altered tumors who had received three initial courses of dose-dense doxorubicin and cyclophosphamide (ddAC), were randomized between a fourth ddAC course followed by high-dose carboplatin-thiotepa-cyclophosphamide or conventional chemotherapy (initially ddAC only or ddAC-capecitabine/decetaxel [CD] depending on MRI response, after amendment ddAC-carboplatin/paclitaxel [CP] for everyone). The primary endpoint was the neoadjuvant response index (NRI). Secondary endpoints included recurrence-free survival (RFS) and overall survival (OS). In total, 122 patients were randomized. No difference in NRI-score distribution (p = 0.41) was found. A statistically non-significant RFS difference was found (HR 0.54; 95% CI 0.23–1.25; p = 0.15). Exploratory RFS analyses showed benefit in stage III (n = 35; HR 0.16; 95% CI 0.03–0.75), but not stage II (n = 86; HR 1.00; 95% CI 0.30–3.30) patients. For stage III, 4-year RFS was 46% (95% CI 24–87%), 71% (95% CI 48–100%) and 88% (95% CI 74–100%), for ddAC/ddAC-CD, ddAC-CP and high-dose chemotherapy, respectively. No significant differences were found between high-dose and conventional chemotherapy in stage II-III, triple-negative, BRCA-altered breast cancer patients. Further research is needed to establish if there are patients with stage III, triple negative BRCA-altered breast cancer for whom outcomes can be improved with high-dose alkylating chemotherapy or whether the current standard neoadjuvant therapy including carboplatin and an immune checkpoint inhibitor is sufficient. Trial Registration: NCT01057069.

Published
2023

2. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours : a multicentre retrospective observational cohort study

Author

Osterlund, P., Kinos, S., Pfeiffer, P., Salminen, T., Kwakman, J. J. M., Frodin, J-E, Shah, C. H., Sorbye, H., Ristamaki, R., Halonen, P., Soveri, L. M., Heerva, E., Algars, A., Barlund, M., Hagman, H., McDermott, R., O'Reilly, M., Röckert, R., Liposits, G., Kallio, R., Flygare, P., Teske, A. J., van Werkhoven, E., Punt, C. J. A., Glimelius, Bengt, Osterlund, P., Kinos, S., Pfeiffer, P., Salminen, T., Kwakman, J. J. M., Frodin, J-E, Shah, C. H., Sorbye, H., Ristamaki, R., Halonen, P., Soveri, L. M., Heerva, E., Algars, A., Barlund, M., Hagman, H., McDermott, R., O'Reilly, M., Röckert, R., Liposits, G., Kallio, R., Flygare, P., Teske, A. J., van Werkhoven, E., Punt, C. J. A., and Glimelius, Bengt

Abstract

Background: Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. S-1 is a fluoropyrimidine with low rates of cardiotoxicity, but evidence regarding the safety of switching to S-1 after 5-FU- or capecitabine-associated cardiotoxicity is scarce. Patients and methods: This retrospective study (NCT04260269) was conducted at 13 centres in 6 countries. The primary endpoint was recurrence of cardiotoxicity after switch to S-1-based treatment due to 5-FU- or capecitabine-related cardiotoxicity: clinically meaningful if the upper boundary of the 95% confidence interval (CI; by competing risk) is not including 15%. Secondary endpoints included cardiac risk factors, diagnostic work-up, treatments, outcomes, and timelines of cardiotoxicity. Results: Per protocol, 200 patients, treated between 2011 and 2020 [median age 66 years (range 19-86); 118 (59%) males], were included. Treatment intent was curative in 145 (73%). Initial cardiotoxicity was due to capecitabine (n = 170), continuous infusion 5-FU (n = 22), or bolus 5-FU (n = 8), which was administered in combination with other chemotherapy, targeted agents, or radiotherapy in 133 patients. Previous cardiovascular comorbidities were present in 99 (50%) patients. Cardiotoxic events (n = 228/200) included chest pain (n = 125), coronary syndrome/ infarction (n = 69), arrhythmia (n = 22), heart failure/cardiomyopathy (n = 7), cardiac arrest (n = 4), and malignant hypertension (n = 1). Cardiotoxicity was severe or life-threatening in 112 (56%) patients and led to permanent capecitabine/5-FU discontinuation in 192 (96%). After switch to S-1, recurrent cardiotoxicity was observed in eight (4%) patients (95% CI 2.02-7.89, primary endpoint met). Events were limited to grade 1-2 and occurred at a median of 16 days (interquartile range 7-67) from therapy switch. Baseline ischemic heart disease was a risk factor for recurrent cardiotoxicity (odds ratio 6.18

Published
2022
Full Text
View/download PDF

3. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours : a multicentre retrospective observational cohort study

Author

Osterlund, P., Kinos, S., Pfeiffer, P., Salminen, T., Kwakman, J. J. M., Frodin, J-E, Shah, C. H., Sorbye, H., Ristamaki, R., Halonen, P., Soveri, L. M., Heerva, E., Algars, A., Barlund, M., Hagman, H., McDermott, R., O'Reilly, M., Röckert, R., Liposits, G., Kallio, R., Flygare, P., Teske, A. J., van Werkhoven, E., Punt, C. J. A., Glimelius, Bengt, Osterlund, P., Kinos, S., Pfeiffer, P., Salminen, T., Kwakman, J. J. M., Frodin, J-E, Shah, C. H., Sorbye, H., Ristamaki, R., Halonen, P., Soveri, L. M., Heerva, E., Algars, A., Barlund, M., Hagman, H., McDermott, R., O'Reilly, M., Röckert, R., Liposits, G., Kallio, R., Flygare, P., Teske, A. J., van Werkhoven, E., Punt, C. J. A., and Glimelius, Bengt

Abstract

Background: Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. S-1 is a fluoropyrimidine with low rates of cardiotoxicity, but evidence regarding the safety of switching to S-1 after 5-FU- or capecitabine-associated cardiotoxicity is scarce. Patients and methods: This retrospective study (NCT04260269) was conducted at 13 centres in 6 countries. The primary endpoint was recurrence of cardiotoxicity after switch to S-1-based treatment due to 5-FU- or capecitabine-related cardiotoxicity: clinically meaningful if the upper boundary of the 95% confidence interval (CI; by competing risk) is not including 15%. Secondary endpoints included cardiac risk factors, diagnostic work-up, treatments, outcomes, and timelines of cardiotoxicity. Results: Per protocol, 200 patients, treated between 2011 and 2020 [median age 66 years (range 19-86); 118 (59%) males], were included. Treatment intent was curative in 145 (73%). Initial cardiotoxicity was due to capecitabine (n = 170), continuous infusion 5-FU (n = 22), or bolus 5-FU (n = 8), which was administered in combination with other chemotherapy, targeted agents, or radiotherapy in 133 patients. Previous cardiovascular comorbidities were present in 99 (50%) patients. Cardiotoxic events (n = 228/200) included chest pain (n = 125), coronary syndrome/ infarction (n = 69), arrhythmia (n = 22), heart failure/cardiomyopathy (n = 7), cardiac arrest (n = 4), and malignant hypertension (n = 1). Cardiotoxicity was severe or life-threatening in 112 (56%) patients and led to permanent capecitabine/5-FU discontinuation in 192 (96%). After switch to S-1, recurrent cardiotoxicity was observed in eight (4%) patients (95% CI 2.02-7.89, primary endpoint met). Events were limited to grade 1-2 and occurred at a median of 16 days (interquartile range 7-67) from therapy switch. Baseline ischemic heart disease was a risk factor for recurrent cardiotoxicity (odds ratio 6.18

Published
2022
Full Text
View/download PDF

4. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours : a multicentre retrospective observational cohort study

Author

Osterlund, P., Kinos, S., Pfeiffer, P., Salminen, T., Kwakman, J. J. M., Frodin, J-E, Shah, C. H., Sorbye, H., Ristamaki, R., Halonen, P., Soveri, L. M., Heerva, E., Algars, A., Barlund, M., Hagman, H., McDermott, R., O'Reilly, M., Röckert, R., Liposits, G., Kallio, R., Flygare, P., Teske, A. J., van Werkhoven, E., Punt, C. J. A., Glimelius, Bengt, Osterlund, P., Kinos, S., Pfeiffer, P., Salminen, T., Kwakman, J. J. M., Frodin, J-E, Shah, C. H., Sorbye, H., Ristamaki, R., Halonen, P., Soveri, L. M., Heerva, E., Algars, A., Barlund, M., Hagman, H., McDermott, R., O'Reilly, M., Röckert, R., Liposits, G., Kallio, R., Flygare, P., Teske, A. J., van Werkhoven, E., Punt, C. J. A., and Glimelius, Bengt

Abstract

Background: Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. S-1 is a fluoropyrimidine with low rates of cardiotoxicity, but evidence regarding the safety of switching to S-1 after 5-FU- or capecitabine-associated cardiotoxicity is scarce. Patients and methods: This retrospective study (NCT04260269) was conducted at 13 centres in 6 countries. The primary endpoint was recurrence of cardiotoxicity after switch to S-1-based treatment due to 5-FU- or capecitabine-related cardiotoxicity: clinically meaningful if the upper boundary of the 95% confidence interval (CI; by competing risk) is not including 15%. Secondary endpoints included cardiac risk factors, diagnostic work-up, treatments, outcomes, and timelines of cardiotoxicity. Results: Per protocol, 200 patients, treated between 2011 and 2020 [median age 66 years (range 19-86); 118 (59%) males], were included. Treatment intent was curative in 145 (73%). Initial cardiotoxicity was due to capecitabine (n = 170), continuous infusion 5-FU (n = 22), or bolus 5-FU (n = 8), which was administered in combination with other chemotherapy, targeted agents, or radiotherapy in 133 patients. Previous cardiovascular comorbidities were present in 99 (50%) patients. Cardiotoxic events (n = 228/200) included chest pain (n = 125), coronary syndrome/ infarction (n = 69), arrhythmia (n = 22), heart failure/cardiomyopathy (n = 7), cardiac arrest (n = 4), and malignant hypertension (n = 1). Cardiotoxicity was severe or life-threatening in 112 (56%) patients and led to permanent capecitabine/5-FU discontinuation in 192 (96%). After switch to S-1, recurrent cardiotoxicity was observed in eight (4%) patients (95% CI 2.02-7.89, primary endpoint met). Events were limited to grade 1-2 and occurred at a median of 16 days (interquartile range 7-67) from therapy switch. Baseline ischemic heart disease was a risk factor for recurrent cardiotoxicity (odds ratio 6.18

Published
2022
Full Text
View/download PDF

5. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours : a multicentre retrospective observational cohort study

Author

Osterlund, P., Kinos, S., Pfeiffer, P., Salminen, T., Kwakman, J. J. M., Frodin, J-E, Shah, C. H., Sorbye, H., Ristamaki, R., Halonen, P., Soveri, L. M., Heerva, E., Algars, A., Barlund, M., Hagman, H., McDermott, R., O'Reilly, M., Röckert, R., Liposits, G., Kallio, R., Flygare, P., Teske, A. J., van Werkhoven, E., Punt, C. J. A., Glimelius, Bengt, Osterlund, P., Kinos, S., Pfeiffer, P., Salminen, T., Kwakman, J. J. M., Frodin, J-E, Shah, C. H., Sorbye, H., Ristamaki, R., Halonen, P., Soveri, L. M., Heerva, E., Algars, A., Barlund, M., Hagman, H., McDermott, R., O'Reilly, M., Röckert, R., Liposits, G., Kallio, R., Flygare, P., Teske, A. J., van Werkhoven, E., Punt, C. J. A., and Glimelius, Bengt

Abstract

Background: Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. S-1 is a fluoropyrimidine with low rates of cardiotoxicity, but evidence regarding the safety of switching to S-1 after 5-FU- or capecitabine-associated cardiotoxicity is scarce. Patients and methods: This retrospective study (NCT04260269) was conducted at 13 centres in 6 countries. The primary endpoint was recurrence of cardiotoxicity after switch to S-1-based treatment due to 5-FU- or capecitabine-related cardiotoxicity: clinically meaningful if the upper boundary of the 95% confidence interval (CI; by competing risk) is not including 15%. Secondary endpoints included cardiac risk factors, diagnostic work-up, treatments, outcomes, and timelines of cardiotoxicity. Results: Per protocol, 200 patients, treated between 2011 and 2020 [median age 66 years (range 19-86); 118 (59%) males], were included. Treatment intent was curative in 145 (73%). Initial cardiotoxicity was due to capecitabine (n = 170), continuous infusion 5-FU (n = 22), or bolus 5-FU (n = 8), which was administered in combination with other chemotherapy, targeted agents, or radiotherapy in 133 patients. Previous cardiovascular comorbidities were present in 99 (50%) patients. Cardiotoxic events (n = 228/200) included chest pain (n = 125), coronary syndrome/ infarction (n = 69), arrhythmia (n = 22), heart failure/cardiomyopathy (n = 7), cardiac arrest (n = 4), and malignant hypertension (n = 1). Cardiotoxicity was severe or life-threatening in 112 (56%) patients and led to permanent capecitabine/5-FU discontinuation in 192 (96%). After switch to S-1, recurrent cardiotoxicity was observed in eight (4%) patients (95% CI 2.02-7.89, primary endpoint met). Events were limited to grade 1-2 and occurred at a median of 16 days (interquartile range 7-67) from therapy switch. Baseline ischemic heart disease was a risk factor for recurrent cardiotoxicity (odds ratio 6.18

Published
2022
Full Text
View/download PDF

6. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours:a multicentre retrospective observational cohort study

Author

Osterlund, P. (P.), Kinos, S. (S.), Pfeiffer, P. (P.), Salminen, T. (T.), Kwakman, J. J. (J. J. M.), Frödin, J.-E. (J.-E.), Shah, C. H. (C. H.), Sorbye, H. (H.), Ristamäki, R. (R.), Halonen, P. (P.), Soveri, L. .. (L .M.), Heervä, E. (E.), Ålgars, A. (A.), Bärlund, M. (M.), Hagman, H. (H.), McDermott, R. (R.), O’Reilly, M. (M.), Röckert, R. (R.), Liposits, G. (G.), Kallio, R. (R.), Flygare, P. (P.), Teske, A. J. (A. J.), van Werkhoven, E. (E.), Punt, C. J. (C. J A.), B. Glimelius, B. G. (B. Glimelius), Osterlund, P. (P.), Kinos, S. (S.), Pfeiffer, P. (P.), Salminen, T. (T.), Kwakman, J. J. (J. J. M.), Frödin, J.-E. (J.-E.), Shah, C. H. (C. H.), Sorbye, H. (H.), Ristamäki, R. (R.), Halonen, P. (P.), Soveri, L. .. (L .M.), Heervä, E. (E.), Ålgars, A. (A.), Bärlund, M. (M.), Hagman, H. (H.), McDermott, R. (R.), O’Reilly, M. (M.), Röckert, R. (R.), Liposits, G. (G.), Kallio, R. (R.), Flygare, P. (P.), Teske, A. J. (A. J.), van Werkhoven, E. (E.), Punt, C. J. (C. J A.), and B. Glimelius, B. G. (B. Glimelius)

Abstract

Background: Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. S-1 is a fluoropyrimidine with low rates of cardiotoxicity, but evidence regarding the safety of switching to S-1 after 5-FU- or capecitabine-associated cardiotoxicity is scarce. Patients and methods: This retrospective study (NCT04260269) was conducted at 13 centres in 6 countries. The primary endpoint was recurrence of cardiotoxicity after switch to S-1-based treatment due to 5-FU- or capecitabine-related cardiotoxicity: clinically meaningful if the upper boundary of the 95% confidence interval (CI; by competing risk) is not including 15%. Secondary endpoints included cardiac risk factors, diagnostic work-up, treatments, outcomes, and timelines of cardiotoxicity. Results: Per protocol, 200 patients, treated between 2011 and 2020 [median age 66 years (range 19-86); 118 (59%) males], were included. Treatment intent was curative in 145 (73%). Initial cardiotoxicity was due to capecitabine (n = 170), continuous infusion 5-FU (n = 22), or bolus 5-FU (n = 8), which was administered in combination with other chemotherapy, targeted agents, or radiotherapy in 133 patients. Previous cardiovascular comorbidities were present in 99 (50%) patients. Cardiotoxic events (n = 228/200) included chest pain (n = 125), coronary syndrome/infarction (n = 69), arrhythmia (n = 22), heart failure/cardiomyopathy (n = 7), cardiac arrest (n = 4), and malignant hypertension (n = 1). Cardiotoxicity was severe or life-threatening in 112 (56%) patients and led to permanent capecitabine/5-FU discontinuation in 192 (96%). After switch to S-1, recurrent cardiotoxicity was observed in eight (4%) patients (95% CI 2.02-7.89, primary endpoint met). Events were limited to grade 1-2 and occurred at a median of 16 days (interquartile range 7-67) from therapy switch. Baseline ischemic heart disease was a risk factor for recurrent cardiotoxicity (odds rat

Published
2022

7. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours : a multicentre retrospective observational cohort study

Author

Osterlund, P., Kinos, S., Pfeiffer, P., Salminen, T., Kwakman, J. J. M., Frodin, J-E, Shah, C. H., Sorbye, H., Ristamaki, R., Halonen, P., Soveri, L. M., Heerva, E., Algars, A., Barlund, M., Hagman, H., McDermott, R., O'Reilly, M., Röckert, R., Liposits, G., Kallio, R., Flygare, P., Teske, A. J., van Werkhoven, E., Punt, C. J. A., Glimelius, Bengt, Osterlund, P., Kinos, S., Pfeiffer, P., Salminen, T., Kwakman, J. J. M., Frodin, J-E, Shah, C. H., Sorbye, H., Ristamaki, R., Halonen, P., Soveri, L. M., Heerva, E., Algars, A., Barlund, M., Hagman, H., McDermott, R., O'Reilly, M., Röckert, R., Liposits, G., Kallio, R., Flygare, P., Teske, A. J., van Werkhoven, E., Punt, C. J. A., and Glimelius, Bengt

Abstract

Background: Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. S-1 is a fluoropyrimidine with low rates of cardiotoxicity, but evidence regarding the safety of switching to S-1 after 5-FU- or capecitabine-associated cardiotoxicity is scarce. Patients and methods: This retrospective study (NCT04260269) was conducted at 13 centres in 6 countries. The primary endpoint was recurrence of cardiotoxicity after switch to S-1-based treatment due to 5-FU- or capecitabine-related cardiotoxicity: clinically meaningful if the upper boundary of the 95% confidence interval (CI; by competing risk) is not including 15%. Secondary endpoints included cardiac risk factors, diagnostic work-up, treatments, outcomes, and timelines of cardiotoxicity. Results: Per protocol, 200 patients, treated between 2011 and 2020 [median age 66 years (range 19-86); 118 (59%) males], were included. Treatment intent was curative in 145 (73%). Initial cardiotoxicity was due to capecitabine (n = 170), continuous infusion 5-FU (n = 22), or bolus 5-FU (n = 8), which was administered in combination with other chemotherapy, targeted agents, or radiotherapy in 133 patients. Previous cardiovascular comorbidities were present in 99 (50%) patients. Cardiotoxic events (n = 228/200) included chest pain (n = 125), coronary syndrome/ infarction (n = 69), arrhythmia (n = 22), heart failure/cardiomyopathy (n = 7), cardiac arrest (n = 4), and malignant hypertension (n = 1). Cardiotoxicity was severe or life-threatening in 112 (56%) patients and led to permanent capecitabine/5-FU discontinuation in 192 (96%). After switch to S-1, recurrent cardiotoxicity was observed in eight (4%) patients (95% CI 2.02-7.89, primary endpoint met). Events were limited to grade 1-2 and occurred at a median of 16 days (interquartile range 7-67) from therapy switch. Baseline ischemic heart disease was a risk factor for recurrent cardiotoxicity (odds ratio 6.18

Published
2022
Full Text
View/download PDF

8. Sex differences in patients with gastrointestinal stromal tumours:do they exist and does it affect survival?

Author

IJzerman, N S, van Werkhoven, E, Mohammadi, M, Hollander, D den, Bleckman, R F, Reyners, A K L, Desar, I M E, Gelderblom, H, Grünhagen, D J, Mathijssen, R H J, Steeghs, N, van der Graaf, W T A, IJzerman, N S, van Werkhoven, E, Mohammadi, M, Hollander, D den, Bleckman, R F, Reyners, A K L, Desar, I M E, Gelderblom, H, Grünhagen, D J, Mathijssen, R H J, Steeghs, N, and van der Graaf, W T A

Abstract

BACKGROUND: Sex differences in cancer have gained attention in recent years. The role of sex as a prognostic factor in gastrointestinal stromal tumours (GIST) has not been well established. The aim of this research was to elucidate potential sex differences in GIST patients and the influence of sex on disease-specific survival (DSS).METHODS: A review of the literature was carried out to obtain an overview of all literature with sex as a covariate on GIST survival analyses. Furthermore, in the Dutch GIST Registry, GIST characteristics between males and females were compared and the influence of sex on DSS was analysed.RESULTS: A total of 118 articles from the review of the literature met our selection criteria; 58% of the articles found no sex difference in survival and 42% did find a sex difference. All differences favoured female patients, although there was substantial overlap of individual patients in the various reported groups. The Dutch GIST Registry cohort consisted of 1425 patients (46% female). Compared with female patients, male patients had larger tumours (mean 9.0 cm versus 7.9 cm) and higher mitotic rates (34.4% versus 28.0% >5 mitoses/5 mm2). GIST in males was more often metastasized at diagnosis (21.3% versus 13.7%) and incurable (38.5% versus 31.0%). Male patients less often received surgery of the primary tumour (71.7% versus 78.9%), but did experience more tumour ruptures (18.2% versus 13.3%). Male patients had a worse DSS than females. This was not statistically significant when corrected for differences in GIST characteristics.CONCLUSIONS: In case of sex differences in GIST in the literature, male patients have a worse outcome. In our Dutch GIST cohort a similar finding was made, but sex was shown not to be an independent factor. Male patients more often had aggressive GISTs, with larger tumours, higher mitotic rates, more tumour ruptures, and metastases, which could explain the sex differences in DSS.

Published
2022

9. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study

Author

MS Medische Oncologie, Team Medisch, Circulatory Health, Epi Kanker Team B, Researchgr. Nucleaire Geneeskunde, Cancer, Osterlund, P, Kinos, S, Pfeiffer, P, Salminen, T, Kwakman, J J M, Frödin, J-E, Shah, C H, Sorbye, H, Ristamäki, R, Halonen, P, Soveri, L M, Heervä, E, Ålgars, A, Bärlund, M, Hagman, H, McDermott, R, O'Reilly, M, Röckert, R, Liposits, G, Kallio, R, Flygare, P, Teske, A J, van Werkhoven, E, Punt, C J A, Glimelius, B, MS Medische Oncologie, Team Medisch, Circulatory Health, Epi Kanker Team B, Researchgr. Nucleaire Geneeskunde, Cancer, Osterlund, P, Kinos, S, Pfeiffer, P, Salminen, T, Kwakman, J J M, Frödin, J-E, Shah, C H, Sorbye, H, Ristamäki, R, Halonen, P, Soveri, L M, Heervä, E, Ålgars, A, Bärlund, M, Hagman, H, McDermott, R, O'Reilly, M, Röckert, R, Liposits, G, Kallio, R, Flygare, P, Teske, A J, van Werkhoven, E, Punt, C J A, and Glimelius, B

Published
2022

10. Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer

Author

Divisie Beeld & Oncologie, Pathologie Pathologen staf, Cancer, Pathologie Moleculair, Externen Med. Onco, van Berge Henegouwen, J M, Jebbink, M, Hoes, L R, van der Wijngaart, H, Zeverijn, L J, van der Velden, D L, Roepman, P, de Leng, W W J, Jansen, A M L, van Werkhoven, E, van der Noort, V, van der Wekken, A J, de Langen, A J, Voest, E E, Verheul, H M W, Smit, E F, Gelderblom, H, Divisie Beeld & Oncologie, Pathologie Pathologen staf, Cancer, Pathologie Moleculair, Externen Med. Onco, van Berge Henegouwen, J M, Jebbink, M, Hoes, L R, van der Wijngaart, H, Zeverijn, L J, van der Velden, D L, Roepman, P, de Leng, W W J, Jansen, A M L, van Werkhoven, E, van der Noort, V, van der Wekken, A J, de Langen, A J, Voest, E E, Verheul, H M W, Smit, E F, and Gelderblom, H

Published
2022

11. Prospective experimental treatment of colorectal cancer patients based on organoid drug responses

Author

MS Medische Oncologie, CMM, CMM Groep Cuppen, Cancer, Ooft, S. N., Weeber, F., Schipper, L., Dijkstra, K. K., McLean, C. M., Kaing, S., van de Haar, J., Prevoo, W., van Werkhoven, E., Snaebjornsson, P., Hoes, L. R., Chalabi, M., van der Velden, D., van Leerdam, M., Boot, H., Grootscholten, C., Huitema, A. D.R., Bloemendal, H. J., Cuppen, E., Voest, E. E., MS Medische Oncologie, CMM, CMM Groep Cuppen, Cancer, Ooft, S. N., Weeber, F., Schipper, L., Dijkstra, K. K., McLean, C. M., Kaing, S., van de Haar, J., Prevoo, W., van Werkhoven, E., Snaebjornsson, P., Hoes, L. R., Chalabi, M., van der Velden, D., van Leerdam, M., Boot, H., Grootscholten, C., Huitema, A. D.R., Bloemendal, H. J., Cuppen, E., and Voest, E. E.

Published
2021

13. High versus low dose Stereotactic Body Radiation Therapy for hepatic metastases

Author

Kok, E.N.D, Jansen, EPM, Heeres, BC, Kok, NFM, Janssen, T, van Werkhoven, E, Sanders, FRK, Ruers, TJM, Nowee, ME, Kuhlmann, KFD, Kok, E.N.D, Jansen, EPM, Heeres, BC, Kok, NFM, Janssen, T, van Werkhoven, E, Sanders, FRK, Ruers, TJM, Nowee, ME, and Kuhlmann, KFD

Abstract

Introduction: Stereotactic Body Radiation Therapy (SBRT) is a treatment option for patients with liver metastases. This study evaluated the impact of high versus low dose image-guided SBRT of hepatic metastases. Methods and materials: This is a single-center retrospective study of patients with liver metastases treated with SBRT. For analyses, patients were divided into two groups: 100 Gy and >100 Gy near-minimum Biological Effective Doses (BED98%). The main outcomes were local control (LC), toxicity and overall survival (OS). Cox regression analyses were performed to determine prognostic variables on LC and OS Results: Ninety patients with 97 liver metastases (77% colorectal) were included. Median follow-up was 28.6 months. The two-year LC rates in the 100 Gy and >100 Gy BED98% group were 60% (CI: 41–80%) and 90% (CI: 80–100%), respectively (p = 0.004). Grade 3 toxicity occurred in 7% vs 2% in the 100 Gy and >100 Gy group (p = 0.23). Two-year OS rates in the 100 Gy and >100 Gy group were 48% (CI: 32–65%) and 85% (CI: 73–97%), respectively (p = 0.007). In multivariable Cox regression analyses, group dose and tumor volume were significantly correlated with LC (HR: 3.61; p = 0.017 and HR: 1.01; p = 0.005) and OS (HR: 2.38; p = 0.005 and HR: 1.01; p = <0.0001). Conclusion: High dose SBRT provides significantly better local control and overall survival than low dose SBRT without increasing toxicity. When surgical resection is not feasible, high dose SBRT provides an effective and safe treatment for liver metastases.

Published
2020

14. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

Author

van der Velden, D L, Hoes, L R, van der Wijngaart, H, van Berge Henegouwen, J M, van Werkhoven, E, Roepman, P, Schilsky, R L, de Leng, W W J, Huitema, A D R, Nuijen, B, Nederlof, P M, van Herpen, C M L, de Groot, D J A, Devriese, L A, Hoeben, A, de Jonge, M J A, Chalabi, M, Smit, E F, de Langen, A J, Mehra, N, Labots, M, Kapiteijn, E, Sleijfer, S, Cuppen, E, Verheul, H M W, Gelderblom, H, Voest, E E, van der Velden, D L, Hoes, L R, van der Wijngaart, H, van Berge Henegouwen, J M, van Werkhoven, E, Roepman, P, Schilsky, R L, de Leng, W W J, Huitema, A D R, Nuijen, B, Nederlof, P M, van Herpen, C M L, de Groot, D J A, Devriese, L A, Hoeben, A, de Jonge, M J A, Chalabi, M, Smit, E F, de Langen, A J, Mehra, N, Labots, M, Kapiteijn, E, Sleijfer, S, Cuppen, E, Verheul, H M W, Gelderblom, H, and Voest, E E

Published
2019

15. Personalised reimbursement : a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients

Author

van Waalwijk van Doorn-Khosrovani, S B, Pisters-van Roy, A, van Saase, L, van der Graaff, M, Gijzen, J, Sleijfer, S, Hoes, L R, van Berge Henegouwen, J M, van der Wijngaart, H, van der Velden, D L, van Werkhoven, E, Retel, V P, van Harten, W H, Huitema, A D R, Timmers, L, Gelderblom, H, Verheul, H M W, Voest, E E, van Waalwijk van Doorn-Khosrovani, S B, Pisters-van Roy, A, van Saase, L, van der Graaff, M, Gijzen, J, Sleijfer, S, Hoes, L R, van Berge Henegouwen, J M, van der Wijngaart, H, van der Velden, D L, van Werkhoven, E, Retel, V P, van Harten, W H, Huitema, A D R, Timmers, L, Gelderblom, H, Verheul, H M W, and Voest, E E

Published
2019

16. Personalised reimbursement : a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients

Author

van Waalwijk van Doorn-Khosrovani, S B, Pisters-van Roy, A, van Saase, L, van der Graaff, M, Gijzen, J, Sleijfer, S, Hoes, L R, van Berge Henegouwen, J M, van der Wijngaart, H, van der Velden, D L, van Werkhoven, E, Retel, V P, van Harten, W H, Huitema, A D R, Timmers, L, Gelderblom, H, Verheul, H M W, Voest, E E, van Waalwijk van Doorn-Khosrovani, S B, Pisters-van Roy, A, van Saase, L, van der Graaff, M, Gijzen, J, Sleijfer, S, Hoes, L R, van Berge Henegouwen, J M, van der Wijngaart, H, van der Velden, D L, van Werkhoven, E, Retel, V P, van Harten, W H, Huitema, A D R, Timmers, L, Gelderblom, H, Verheul, H M W, and Voest, E E

Published
2019

17. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

Author

van der Velden, D L, Hoes, L R, van der Wijngaart, H, van Berge Henegouwen, J M, van Werkhoven, E, Roepman, P, Schilsky, R L, de Leng, W W J, Huitema, A D R, Nuijen, B, Nederlof, P M, van Herpen, C M L, de Groot, D J A, Devriese, L A, Hoeben, A, de Jonge, M J A, Chalabi, M, Smit, E F, de Langen, A J, Mehra, N, Labots, M, Kapiteijn, E, Sleijfer, S, Cuppen, E, Verheul, H M W, Gelderblom, H, Voest, E E, van der Velden, D L, Hoes, L R, van der Wijngaart, H, van Berge Henegouwen, J M, van Werkhoven, E, Roepman, P, Schilsky, R L, de Leng, W W J, Huitema, A D R, Nuijen, B, Nederlof, P M, van Herpen, C M L, de Groot, D J A, Devriese, L A, Hoeben, A, de Jonge, M J A, Chalabi, M, Smit, E F, de Langen, A J, Mehra, N, Labots, M, Kapiteijn, E, Sleijfer, S, Cuppen, E, Verheul, H M W, Gelderblom, H, and Voest, E E

Published
2019

18. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Haan, R, van Werkhoven, E, van den Heuvel, M M, Peulen, H M U, Sonke, G S, Elkhuizen, P, van den Brekel, M W M, Tesselaar, M E T, Vens, C, Schellens, J H M, van Triest, B, Verheij, M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Haan, R, van Werkhoven, E, van den Heuvel, M M, Peulen, H M U, Sonke, G S, Elkhuizen, P, van den Brekel, M W M, Tesselaar, M E T, Vens, C, Schellens, J H M, van Triest, B, and Verheij, M

Published
2019

19. Personalised reimbursement : a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients

Author

van Waalwijk van Doorn-Khosrovani, S B, Pisters-van Roy, A, van Saase, L, van der Graaff, M, Gijzen, J, Sleijfer, S, Hoes, L R, van Berge Henegouwen, J M, van der Wijngaart, H, van der Velden, D L, van Werkhoven, E, Retel, V P, van Harten, W H, Huitema, A D R, Timmers, L, Gelderblom, H, Verheul, H M W, Voest, E E, van Waalwijk van Doorn-Khosrovani, S B, Pisters-van Roy, A, van Saase, L, van der Graaff, M, Gijzen, J, Sleijfer, S, Hoes, L R, van Berge Henegouwen, J M, van der Wijngaart, H, van der Velden, D L, van Werkhoven, E, Retel, V P, van Harten, W H, Huitema, A D R, Timmers, L, Gelderblom, H, Verheul, H M W, and Voest, E E

Published
2019

20. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

Author

van der Velden, D L, Hoes, L R, van der Wijngaart, H, van Berge Henegouwen, J M, van Werkhoven, E, Roepman, P, Schilsky, R L, de Leng, W W J, Huitema, A D R, Nuijen, B, Nederlof, P M, van Herpen, C M L, de Groot, D J A, Devriese, L A, Hoeben, A, de Jonge, M J A, Chalabi, M, Smit, E F, de Langen, A J, Mehra, N, Labots, M, Kapiteijn, E, Sleijfer, S, Cuppen, E, Verheul, H M W, Gelderblom, H, Voest, E E, van der Velden, D L, Hoes, L R, van der Wijngaart, H, van Berge Henegouwen, J M, van Werkhoven, E, Roepman, P, Schilsky, R L, de Leng, W W J, Huitema, A D R, Nuijen, B, Nederlof, P M, van Herpen, C M L, de Groot, D J A, Devriese, L A, Hoeben, A, de Jonge, M J A, Chalabi, M, Smit, E F, de Langen, A J, Mehra, N, Labots, M, Kapiteijn, E, Sleijfer, S, Cuppen, E, Verheul, H M W, Gelderblom, H, and Voest, E E

Published
2019

21. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Haan, R, van Werkhoven, E, van den Heuvel, M M, Peulen, H M U, Sonke, G S, Elkhuizen, P, van den Brekel, M W M, Tesselaar, M E T, Vens, C, Schellens, J H M, van Triest, B, Verheij, M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Haan, R, van Werkhoven, E, van den Heuvel, M M, Peulen, H M U, Sonke, G S, Elkhuizen, P, van den Brekel, M W M, Tesselaar, M E T, Vens, C, Schellens, J H M, van Triest, B, and Verheij, M

Published
2019

22. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients

Author

Cancer, Apotheek Onderzoek, van Waalwijk van Doorn-Khosrovani, S B, Pisters-van Roy, A, van Saase, L, van der Graaff, M, Gijzen, J, Sleijfer, S, Hoes, L R, van Berge Henegouwen, J M, van der Wijngaart, H, van der Velden, D L, van Werkhoven, E, Retel, V P, van Harten, W H, Huitema, A D R, Timmers, L, Gelderblom, H, Verheul, H M W, Voest, E E, Cancer, Apotheek Onderzoek, van Waalwijk van Doorn-Khosrovani, S B, Pisters-van Roy, A, van Saase, L, van der Graaff, M, Gijzen, J, Sleijfer, S, Hoes, L R, van Berge Henegouwen, J M, van der Wijngaart, H, van der Velden, D L, van Werkhoven, E, Retel, V P, van Harten, W H, Huitema, A D R, Timmers, L, Gelderblom, H, Verheul, H M W, and Voest, E E

Published
2019

23. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

Author

Pathologie Pathologen staf, Cancer, Apotheek Onderzoek, MS Medische Oncologie, CMM Groep Cuppen, CMM, Externen Med. Onco, van der Velden, D L, Hoes, L R, van der Wijngaart, H, van Berge Henegouwen, J M, van Werkhoven, E, Roepman, P, Schilsky, R L, de Leng, W W J, Huitema, A D R, Nuijen, B, Nederlof, P M, van Herpen, C M L, de Groot, D J A, Devriese, L A, Hoeben, A, de Jonge, M J A, Chalabi, M, Smit, E F, de Langen, A J, Mehra, N, Labots, M, Kapiteijn, E, Sleijfer, S, Cuppen, E, Verheul, H M W, Gelderblom, H, Voest, E E, Pathologie Pathologen staf, Cancer, Apotheek Onderzoek, MS Medische Oncologie, CMM Groep Cuppen, CMM, Externen Med. Onco, van der Velden, D L, Hoes, L R, van der Wijngaart, H, van Berge Henegouwen, J M, van Werkhoven, E, Roepman, P, Schilsky, R L, de Leng, W W J, Huitema, A D R, Nuijen, B, Nederlof, P M, van Herpen, C M L, de Groot, D J A, Devriese, L A, Hoeben, A, de Jonge, M J A, Chalabi, M, Smit, E F, de Langen, A J, Mehra, N, Labots, M, Kapiteijn, E, Sleijfer, S, Cuppen, E, Verheul, H M W, Gelderblom, H, and Voest, E E

Published
2019

24. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Haan, R, van Werkhoven, E, van den Heuvel, M M, Peulen, H M U, Sonke, G S, Elkhuizen, P, van den Brekel, M W M, Tesselaar, M E T, Vens, C, Schellens, J H M, van Triest, B, Verheij, M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Haan, R, van Werkhoven, E, van den Heuvel, M M, Peulen, H M U, Sonke, G S, Elkhuizen, P, van den Brekel, M W M, Tesselaar, M E T, Vens, C, Schellens, J H M, van Triest, B, and Verheij, M

Published
2019

26. Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids

Author

van der Velden, Daphne L., Cirkel, Geert A., Houthuijzen, Julia M., van Werkhoven, E., Roodhart, Jeanine M.L., Daenen, Laura G.M., Kaing, Sovann, Gerrits, Johan, Verhoeven-Duif, Nanda M., Grootscholten, Cecile, Boot, Henk, Sessa, Cristisiana, Bloemendal, Haiko J., de Vos, Filip Y., Voest, Emile E., van der Velden, Daphne L., Cirkel, Geert A., Houthuijzen, Julia M., van Werkhoven, E., Roodhart, Jeanine M.L., Daenen, Laura G.M., Kaing, Sovann, Gerrits, Johan, Verhoeven-Duif, Nanda M., Grootscholten, Cecile, Boot, Henk, Sessa, Cristisiana, Bloemendal, Haiko J., de Vos, Filip Y., and Voest, Emile E.

Published
2018

28. Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids

Author

van der Velden, Daphne L., Cirkel, Geert A., Houthuijzen, Julia M., van Werkhoven, E., Roodhart, Jeanine M.L., Daenen, Laura G.M., Kaing, Sovann, Gerrits, Johan, Verhoeven-Duif, Nanda M., Grootscholten, Cecile, Boot, Henk, Sessa, Cristisiana, Bloemendal, Haiko J., de Vos, Filip Y., Voest, Emile E., van der Velden, Daphne L., Cirkel, Geert A., Houthuijzen, Julia M., van Werkhoven, E., Roodhart, Jeanine M.L., Daenen, Laura G.M., Kaing, Sovann, Gerrits, Johan, Verhoeven-Duif, Nanda M., Grootscholten, Cecile, Boot, Henk, Sessa, Cristisiana, Bloemendal, Haiko J., de Vos, Filip Y., and Voest, Emile E.

Published
2018

30. Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids

Author

van der Velden, Daphne L., Cirkel, Geert A., Houthuijzen, Julia M., van Werkhoven, E., Roodhart, Jeanine M.L., Daenen, Laura G.M., Kaing, Sovann, Gerrits, Johan, Verhoeven-Duif, Nanda M., Grootscholten, Cecile, Boot, Henk, Sessa, Cristisiana, Bloemendal, Haiko J., de Vos, Filip Y., Voest, Emile E., van der Velden, Daphne L., Cirkel, Geert A., Houthuijzen, Julia M., van Werkhoven, E., Roodhart, Jeanine M.L., Daenen, Laura G.M., Kaing, Sovann, Gerrits, Johan, Verhoeven-Duif, Nanda M., Grootscholten, Cecile, Boot, Henk, Sessa, Cristisiana, Bloemendal, Haiko J., de Vos, Filip Y., and Voest, Emile E.

Published
2018

31. Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids

Author

Divisie Beeld & Oncologie, Cancer, Externen Med. Onco, Unit Opleiding Aios, Genetica Lab. Metabole Diagnostiek, MS Medische Oncologie, van der Velden, Daphne L., Cirkel, Geert A., Houthuijzen, Julia M., van Werkhoven, E., Roodhart, Jeanine M.L., Daenen, Laura G.M., Kaing, Sovann, Gerrits, Johan, Verhoeven-Duif, Nanda M., Grootscholten, Cecile, Boot, Henk, Sessa, Cristisiana, Bloemendal, Haiko J., de Vos, Filip Y., Voest, Emile E., Divisie Beeld & Oncologie, Cancer, Externen Med. Onco, Unit Opleiding Aios, Genetica Lab. Metabole Diagnostiek, MS Medische Oncologie, van der Velden, Daphne L., Cirkel, Geert A., Houthuijzen, Julia M., van Werkhoven, E., Roodhart, Jeanine M.L., Daenen, Laura G.M., Kaing, Sovann, Gerrits, Johan, Verhoeven-Duif, Nanda M., Grootscholten, Cecile, Boot, Henk, Sessa, Cristisiana, Bloemendal, Haiko J., de Vos, Filip Y., and Voest, Emile E.

Published
2018

32. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome

Author

de Vries Schultink, A. H M, Alexi, X., van Werkhoven, E., Madlensky, L., Natarajan, L., Flatt, S. W., Zwart, W., Linn, S.C., Parker, B. A., Wu, A. H B, Pierce, J. P., Huitema, A. D R, Beijnen, J. H., de Vries Schultink, A. H M, Alexi, X., van Werkhoven, E., Madlensky, L., Natarajan, L., Flatt, S. W., Zwart, W., Linn, S.C., Parker, B. A., Wu, A. H B, Pierce, J. P., Huitema, A. D R, and Beijnen, J. H.

Published
2017

33. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome

Author

de Vries Schultink, A. H M, Alexi, X., van Werkhoven, E., Madlensky, L., Natarajan, L., Flatt, S. W., Zwart, W., Linn, S.C., Parker, B. A., Wu, A. H B, Pierce, J. P., Huitema, A. D R, Beijnen, J. H., de Vries Schultink, A. H M, Alexi, X., van Werkhoven, E., Madlensky, L., Natarajan, L., Flatt, S. W., Zwart, W., Linn, S.C., Parker, B. A., Wu, A. H B, Pierce, J. P., Huitema, A. D R, and Beijnen, J. H.

Published
2017

34. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Vries Schultink, Aurelia H M, Alexi, X, van Werkhoven, E., Madlensky, L, Natarajan, L, Flatt, S W, Zwart, Wilbert, Linn, Sabine C., Parker, B A, Wu, A H B, Pierce, J P, Huitema, Alwin D R, Beijnen, J H, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Vries Schultink, Aurelia H M, Alexi, X, van Werkhoven, E., Madlensky, L, Natarajan, L, Flatt, S W, Zwart, Wilbert, Linn, Sabine C., Parker, B A, Wu, A H B, Pierce, J P, Huitema, Alwin D R, and Beijnen, J H

Published
2017

35. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome

Author

de Vries Schultink, A. H M, Alexi, X., van Werkhoven, E., Madlensky, L., Natarajan, L., Flatt, S. W., Zwart, W., Linn, S.C., Parker, B. A., Wu, A. H B, Pierce, J. P., Huitema, A. D R, Beijnen, J. H., de Vries Schultink, A. H M, Alexi, X., van Werkhoven, E., Madlensky, L., Natarajan, L., Flatt, S. W., Zwart, W., Linn, S.C., Parker, B. A., Wu, A. H B, Pierce, J. P., Huitema, A. D R, and Beijnen, J. H.

Published
2017

36. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Vries Schultink, Aurelia H M, Alexi, X, van Werkhoven, E., Madlensky, L, Natarajan, L, Flatt, S W, Zwart, Wilbert, Linn, Sabine C., Parker, B A, Wu, A H B, Pierce, J P, Huitema, Alwin D R, Beijnen, J H, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Vries Schultink, Aurelia H M, Alexi, X, van Werkhoven, E., Madlensky, L, Natarajan, L, Flatt, S W, Zwart, Wilbert, Linn, Sabine C., Parker, B A, Wu, A H B, Pierce, J P, Huitema, Alwin D R, and Beijnen, J H

Published
2017

37. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Vries Schultink, Aurelia H M, Alexi, X, van Werkhoven, E., Madlensky, L, Natarajan, L, Flatt, S W, Zwart, Wilbert, Linn, Sabine C., Parker, B A, Wu, A H B, Pierce, J P, Huitema, Alwin D R, Beijnen, J H, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Vries Schultink, Aurelia H M, Alexi, X, van Werkhoven, E., Madlensky, L, Natarajan, L, Flatt, S W, Zwart, Wilbert, Linn, Sabine C., Parker, B A, Wu, A H B, Pierce, J P, Huitema, Alwin D R, and Beijnen, J H

Published
2017

38. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome

Author

Pathologie, Cancer, UMC Utrecht, Apotheek Onderzoek, de Vries Schultink, A. H M, Alexi, X., van Werkhoven, E., Madlensky, L., Natarajan, L., Flatt, S. W., Zwart, W., Linn, S.C., Parker, B. A., Wu, A. H B, Pierce, J. P., Huitema, A. D R, Beijnen, J. H., Pathologie, Cancer, UMC Utrecht, Apotheek Onderzoek, de Vries Schultink, A. H M, Alexi, X., van Werkhoven, E., Madlensky, L., Natarajan, L., Flatt, S. W., Zwart, W., Linn, S.C., Parker, B. A., Wu, A. H B, Pierce, J. P., Huitema, A. D R, and Beijnen, J. H.

Published
2017

39. Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study

Author

Weeber, F, Cirkel, GA, Hoogstraat, M, Bins, Sander, Gadellaa-van Hooijdonk, CGM, Veldhuis, WB, Ooft, S, van Werkhoven, E, Williems, SM, van Stralen, M, Besselink, N J M, Horlings, HM, Steeghs, N, de Jonge, Maja, Langenberg, M H G, Wessels, LFA, Cuppen, E, Schellens, JH, Sleijfer, Stefan, Lolkema, Martijn, Voest, EE, Weeber, F, Cirkel, GA, Hoogstraat, M, Bins, Sander, Gadellaa-van Hooijdonk, CGM, Veldhuis, WB, Ooft, S, van Werkhoven, E, Williems, SM, van Stralen, M, Besselink, N J M, Horlings, HM, Steeghs, N, de Jonge, Maja, Langenberg, M H G, Wessels, LFA, Cuppen, E, Schellens, JH, Sleijfer, Stefan, Lolkema, Martijn, and Voest, EE

Published
2017

41. The time to progression ratio : A new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies

Author

Cirkel, G. A., Weeber, F., Bins, S., Gadellaa-van Hooijdonk, C. G M, van Werkhoven, E., Willems, S. M., van Stralen, M., Veldhuis, W. B., Ubink, I., Steeghs, N., de Jonge, M. J., Langenberg, M. H G, Schellens, J. H M, Sleijfer, S., Lolkema, M. P., Voest, Emile E., Cirkel, G. A., Weeber, F., Bins, S., Gadellaa-van Hooijdonk, C. G M, van Werkhoven, E., Willems, S. M., van Stralen, M., Veldhuis, W. B., Ubink, I., Steeghs, N., de Jonge, M. J., Langenberg, M. H G, Schellens, J. H M, Sleijfer, S., Lolkema, M. P., and Voest, Emile E.

Published
2016

43. The time to progression ratio : A new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies

Author

Cirkel, G. A., Weeber, F., Bins, S., Gadellaa-van Hooijdonk, C. G M, van Werkhoven, E., Willems, S. M., van Stralen, M., Veldhuis, W. B., Ubink, I., Steeghs, N., de Jonge, M. J., Langenberg, M. H G, Schellens, J. H M, Sleijfer, S., Lolkema, M. P., Voest, Emile E., Cirkel, G. A., Weeber, F., Bins, S., Gadellaa-van Hooijdonk, C. G M, van Werkhoven, E., Willems, S. M., van Stralen, M., Veldhuis, W. B., Ubink, I., Steeghs, N., de Jonge, M. J., Langenberg, M. H G, Schellens, J. H M, Sleijfer, S., Lolkema, M. P., and Voest, Emile E.

Published
2016

44. The time to progression ratio:: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies

Author

Sub Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Cirkel, G.A., Weeber, F., Bins, Sander, drs. Gadellaa-van Hooijdonk, C.G.M., van Werkhoven, E., Willems, S.M., van Stralen, M., Veldhuis, W.B., Ubink, I., Steeghs, Neeltje, de Jonge, M.J., Langenberg, M.H., Schellens, J.H.M., Sleijfer, S., Lolkema, M.P., Voest, Emile E, Sub Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Cirkel, G.A., Weeber, F., Bins, Sander, drs. Gadellaa-van Hooijdonk, C.G.M., van Werkhoven, E., Willems, S.M., van Stralen, M., Veldhuis, W.B., Ubink, I., Steeghs, Neeltje, de Jonge, M.J., Langenberg, M.H., Schellens, J.H.M., Sleijfer, S., Lolkema, M.P., and Voest, Emile E

Published
2016

45. The performance of model-based versus rule-based phase I clinical trials in oncology: A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years

Author

Sub Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, van Brummelen, E M J, Huitema, A D R, van Werkhoven, E, Beijnen, J H, Schellens, J H M, Sub Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, van Brummelen, E M J, Huitema, A D R, van Werkhoven, E, Beijnen, J H, and Schellens, J H M

Published
2016

47. The time to progression ratio : A new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies

Author

Cirkel, G. A., Weeber, F., Bins, S., Gadellaa-van Hooijdonk, C. G M, van Werkhoven, E., Willems, S. M., van Stralen, M., Veldhuis, W. B., Ubink, I., Steeghs, N., de Jonge, M. J., Langenberg, M. H G, Schellens, J. H M, Sleijfer, S., Lolkema, M. P., Voest, Emile E., Cirkel, G. A., Weeber, F., Bins, S., Gadellaa-van Hooijdonk, C. G M, van Werkhoven, E., Willems, S. M., van Stralen, M., Veldhuis, W. B., Ubink, I., Steeghs, N., de Jonge, M. J., Langenberg, M. H G, Schellens, J. H M, Sleijfer, S., Lolkema, M. P., and Voest, Emile E.

Published
2016

48. The time to progression ratio:: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies

Author

Sub Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Cirkel, G.A., Weeber, F., Bins, Sander, drs. Gadellaa-van Hooijdonk, C.G.M., van Werkhoven, E., Willems, S.M., van Stralen, M., Veldhuis, W.B., Ubink, I., Steeghs, Neeltje, de Jonge, M.J., Langenberg, M.H., Schellens, J.H.M., Sleijfer, S., Lolkema, M.P., Voest, Emile E, Sub Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Cirkel, G.A., Weeber, F., Bins, Sander, drs. Gadellaa-van Hooijdonk, C.G.M., van Werkhoven, E., Willems, S.M., van Stralen, M., Veldhuis, W.B., Ubink, I., Steeghs, Neeltje, de Jonge, M.J., Langenberg, M.H., Schellens, J.H.M., Sleijfer, S., Lolkema, M.P., and Voest, Emile E

Published
2016

49. The performance of model-based versus rule-based phase I clinical trials in oncology: A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years

Author

Sub Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, van Brummelen, E M J, Huitema, A D R, van Werkhoven, E, Beijnen, J H, Schellens, J H M, Sub Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, van Brummelen, E M J, Huitema, A D R, van Werkhoven, E, Beijnen, J H, and Schellens, J H M

Published
2016

50. Very low local recurrence rates after breast-conserving therapy: Analysis of 8485 patients treated over a 28-year period

Author

Pathologie, Cancer, Pathologie mortuarium en obductie, Bosma, Sophie C J, Van Der Leij, F., van Werkhoven, E., Bartelink, H., Wesseling, J., Linn, S., Rutgers, E J Th, van de Vijver, Marc J, Elkhuizen, Paula H M, Pathologie, Cancer, Pathologie mortuarium en obductie, Bosma, Sophie C J, Van Der Leij, F., van Werkhoven, E., Bartelink, H., Wesseling, J., Linn, S., Rutgers, E J Th, van de Vijver, Marc J, and Elkhuizen, Paula H M

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results